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Combination Therapy of Angiotensin Converting
Enzyme Inhibitor and Angiotensin AT1 Receptor
Antagonist in Diabetic Nephropathy
Tomoyuki Saito, Takako Saito, Hiroyuki Tamemoto, Miho Yuzawa, Masami Sasaki,
Aki Ikoma, Masanobu Kawakami, San-e Ishikawa
Background: The present study was undertaken to determine whether combination therapy of angiotensin
converting enzyme inhibitor (ACEI) and angiotensin AT1 receptor antagonist (ARA) is a useful tool for reducing
albuminuria in diabetic nephropathy.
Methods: Thirty-four subjects with diabetic nephropathy were enrolled in the present study. All the subjects
had hypertension and urinary albumin index (UAI) < 1,000 mg/g creatinine. They were divided into three
groups. Group 1 of 16 subjects was initially treated with imidapril (5–10 mg). Group 2 of eight subjects had
losartan (50–100 mg) added to consecutive therapy with imidapril. Group 3 of 10 subjects had imidapril (5–10
mg) added to consecutive therapy with losartan. Blood pressure and UAI were determined before and 3 and 6
months after the start of the present study.
Results: Blood pressure was significantly decreased in Group 1 subjects. Blood pressure was also reduced in
Groups 2 and 3, but its reduction was not significant. Imidapril significantly reduced UAI in Group 1, from
213.1 ± 46.6 to 111.6 ± 35.6 (p < 0.001) and 114.5 ± 35.4 mg/g creatinine (p < 0.01) 3 and 6 months after
imidapril treatment, respectively. The addition of losartan further reduced UAI in Group 2, who had been
treated with imidapril. UAI decreased from 328.8 ± 87.3 to 185.3 ± 51.4 (p < 0.05) and 244.8 ± 88.3 mg/g
creatinine 3 and 6 months after the addition of losartan, respectively. In contrast, the addition of imidapril to
losartan therapy did not alter UAI in Group 3.
Conclusion: These results indicate that the addition of ARA to consecutive therapy with ACEI augments a
protective effect against the progression of diabetic nephropathy. [Hong Kong J Nephrol 2007;9(1):31–5]
Key words: albuminuria, angiotensin AT1 receptor antagonist, angiotensin converting enzyme
inhibitor, combination therapy, diabetic nephropathy
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INTRODUCTION
Diabetic nephropathy is the major cause of end-stage
renal disease, which is increasing year by year. Inter-
vention for prevention and delaying the progression of
end-stage renal disease is an important issue. The
evidence that the control of blood glucose and blood
pressure is effective for diabetic nephropathy is already
established [1–5]. However, there is limited effective
intervention, except for plasma glucose and blood
pressure control at present. The renal hemodynamic
effect of angiotensin II plays a role in the development
of nephropathy in diabetic subjects [6]. Angiotensin II
is a strong vasoconstrictor hormone. There are afferent
and efferent arterioles in glomerulus, and angiotensin
II specifically constricts efferent arterioles, and thus
provides intraglomerular hypertension. Besides, an-
giotensin II has many additional actions, including
vascular smooth muscle cell proliferation, collagen
synthesis, superoxide production, platelet aggregation,
plasminogen activator inhibitor-1 (PAI-1) activation,
and others [6–8]. It is evident that inhibition of the
renin–angiotensin system prevents the development of
diabetic nephropathy. There are two classes of drugs,
namely, angiotensin converting enzyme inhibitor
(ACEI) and angiotensin AT1 receptor antagonist
(ARA), and their therapeutic efficacy has been proven
in diabetic nephropathy [9–17]. Because there are some
differences in the pharmacologic action between ACEI
and ARA, renoprotective effect is not always uniform
[18]. Several studies have depicted the beneficial effect
of a combination therapy of these two agents [17,19,
20]. In the present study, we determined whether
combination therapy with ACEI and ARA is effective
in reducing albuminuria in diabetic subjects.
SUBJECTS AND METHODS
Subjects
Thirty-four subjects with type 2 diabetes mellitus were
enrolled in the present study between January 2003 and
May 2005. There were 19 males and 15 females, with a
mean age of 65.4 ± 8.7 years (range, 36–77 years). All
subjects had been attending the outpatient clinic of Jichi
Medical University Omiya Medical Center. They had
hypertension and albuminuria < 1,000 mg/g creatinine.
They were subgrouped into three groups according to
the administration of imidapril, an ACEI, and/or losartan,
an ARA. Group 1 included 16 subjects (7 males; 9
females) who were initially started on imidapril 5 mg/
  !"#$%&'()*+,-./0'1=^`bf= !=^o^= !"#$%&'
 !"
day. The dose was increased to a maximum of 10 mg/
day during the observation period. Group 2 included eight
subjects (5 males; 3 females). The subjects had taken
imidapril 10 mg/day for at least 6 months, and began to
take losartan 50 mg/day as a second drug. The dose of
losartan was increased to 100 mg/day 3 months after the
start of the present study in all eight subjects. Group 3
included 10 subjects (7 males; 3 females). They had taken
losartan 100 mg/day for at least 6 months, and then began
to take a second agent of imidapril 5 mg/day. The dose
of imidapril was increased to 10 mg/day 3 months after
the start of the present study in all 10 subjects. The
subjects had been treated at our outpatient clinic for an
additional 6 months. During this observation period,
urinary excretion of albumin was determined at 3 and 6
months. We excluded subjects who had advanced renal
diseases with serum creatinine level > 2 mg/dL, chronic
liver dysfunction, chronic heart disease, inflammatory
disease or malignant tumors. Urinary excretion of
albumin was defined as urinary albumin index (UAI), as
noted below. Blood samples were collected after an
overnight fast to determine fasting plasma glucose,
hemoglobin A1c, serum total cholesterol, high-density
lipoprotein (HDL) cholesterol, triglyceride, serum
sodium, potassium and chloride, blood urea nitrogen
(BUN), creatinine and uric acid. The present study was
approved by the ethics committee of Jichi Medical
University for human studies. We obtained informed
consent from all the subjects who joined the present
protocol.
Measurements
Spot urine samples were collected in the morning when
the subjects were attending the outpatient clinic.
Urinary concentration of albumin was determined by
latex agglutination immunoassay (Eiken, Tokyo, Japan).
Urinary creatinine was measured by enzymatic assay.
UAI (mg/g creatinine) was defined as urinary albumin
concentration (µg/mL) divided by urinary creatinine
level (mg/mL).
Statistical analysis
All values were expressed as mean ± standard error of
the mean. The values were analyzed by analysis of
variance (ANOVA) and Student’s paired t test, when
appropriate. Categorical variables were analyzed by χ2
test. Logarithmic transformation of UAI was used
because of widely distributed UAI. The statistical
package StatView version 5.0 (SAS Institute Inc., Cary,
NC, USA) was used for the present analysis. A p value
< 0.05 was considered significant.
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RESULTS
Table 1 shows the clinical characteristics of all the
subjects with diabetic nephropathy. There were no
differences in age, systolic and diastolic blood pressure,
fasting plasma glucose, hemoglobin A1c, total
cholesterol, HDL cholesterol and triglyceride among
the three groups of subjects. The numbers of subjects
with retinopathy were significantly increased in Groups
2 and 3 compared to in Group 1 (p < 0.001), indicating
that the subjects of Groups 2 and 3 might have
considerably advanced diabetic complications.
Table 2 shows blood pressure, serum electrolytes
and renal function during the observation period in the
three groups of subjects with diabetic nephropathy.
There was no difference in all the basal values among
the three groups of subjects. In Group 1, systolic blood
pressure was significantly decreased 3 and 6 months
after the administration of imidapril. Diastolic blood
pressure was also reduced significantly 3 and 6 months
after the administration of imidapril. Systolic and
diastolic blood pressures were also reduced in Groups
2 and 3, but the reduction was not statistically
significant. BUN and serum creatinine were in the
normal ranges, and they remained unchanged during
the 6-month observation period. Estimated glomerular
filtration rate (GFR) was also in the normal range, and
they remained unchanged during the 6-month period.
Table 1. Clinical characteristics of all subjects with diabetic nephropathy*
Group 1 Group 2 Group 3
(n = 16) (n = 8) (n = 10)
Age, yr 65.9 ± 1.9 63.6 ± 4.6 66.0 ± 2.2
Sex (M/F), n 7/9 5/3 7/3
DM retinopathy, n (%) 5 (31) 6 (75)† 7 (70)†
Hyperlipidemia, n (%) 6 (38) 1 (13) 2 (20)
Ischemic heart disease, n (%) 0 (0) 1 (13) 0 (0)
Systolic BP, mmHg 148.3 ± 3.2 156.4 ± 4.6 149.8 ± 4.1
Diastolic BP, mmHg 84.1 ± 1.6 80.1 ± 3.8 79.9 ± 3.7
Fasting plasma glucose, mg/dL 148.8 ± 14.6 185.1 ± 19.1 143.6 ± 11.7
HbA1c, % 7.7 ± 0.5 7.7 ± 0.4 7.7 ± 0.4
Total cholesterol, mg/dL 203.3 ± 6.7 206.1 ± 8.8 202.1 ± 9.7
HDL cholesterol, mg/dL 53.6 ± 2.3 49.4 ± 3.2 61.0 ± 6.0
Triglycerides, mg/dL 139.3 ± 15.5 169.3 ± 22.4 113.4 ± 17.8
Therapy, n (%)
Diet 0 (0) 1 (13) 0 (0)
OHA 13 (81) 5 (63) 9 (90)
Insulin 3 (19) 2 (25) 1 (10)
*Data are presented as mean ± standard error of the mean; †p < 0.001 vs. Group 1. DM = diabetes mellitus; BP = blood pressure;
HDL = high-density lipoprotein; OHA = oral hypoglycemic agents.
Table 2. Blood pressure, serum electrolytes and renal function during the observation period in the three groups of subjects with diabetic
nephropathy*
Group 1 Group 2 Group 3
0 mo 3 mo 6 mo 0 mo 3 mo 6 mo 0 mo 3 mo 6 mo
Systolic BP, mmHg 148 ± 3.2 139.8 ± 3.1† 141.3 ± 4.3 156.4 ± 4.6 150.3 ± 4.4 142.0 ± 4.9 149.8 ± 4.1 144.1 ± 4.8 147.6 ± 3.7
Diastolic BP, mmHg 85.1 ± 1.6 77.1 ± 2.2† 79.5 ± 2.4† 80.1 ± 3.8 81.9 ± 2.8 76.8 ± 1.1 79.9 ± 3.7 76.3 ± 2.6 85.6 ± 3.4
Serum Na, mmol/L 140.6 ± 0.8 140.2 ± 0.7 140.9 ± 0.5 140.9 ± 0.7 141.0 ± 0.8 139.9 ± 0.7 139.5 ± 1.1 140.0 ± 0.8 138.5 ± 1.1
Serum K, mmol/L 4.2 ± 0.1 4.3 ± 0.1 4.4 ± 0.1 4.3 ± 0.1 4.4 ± 0.2 4.4 ± 0.2 4.3 ± 0.1 4.5 ± 0.2 4.4 ± 0.2
Serum Cl, mmol/L 101.3 ± 0.5 102.3 ± 0.9 103.2 ± 0.6 101.5 ± 0.4 103.1 ± 0.9 102.1 ± 0.7 101.3 ± 1.3 102.7 ± 0.8 101.5 ± 0.8
BUN, mg/dL 13.4 ± 0.9 14.8 ± 1.7 15.3 ± 1.1 12.9 ± 1.1 13.7 ± 1.4 15.4 ± 1.8 15.9 ± 1.3 15.0 ± 1.4 18.6 ± 2.1
Serum Cr, mg/dL 0.60 ± 0.05 0.72 ± 0.08 0.69 ± 0.07 0.66 ± 0.06 0.71 ± 0.05 0.68 ± 0.05 0.76 ± 0.05 0.73 ± 0.05 0.83 ± 0.07
Estimated GFR, mL/min 109.0 ± 9.1 100.5 ± 6.9 101.6 ± 6.8 109.3 ± 9.0 104.6 ± 7.6 103.3 ± 6.5 92.7 ± 7.3 92.8 ± 7.7 93.6 ± 8.6
Serum uric acid, mg/dL 5.0 ± 0.5 5.2 ± 0.6 5.3 ± 0.5 5.7 ± 0.5 5.9 ± 0.4 5.7 ± 0.5 4.5 ± 0.2 4.3 ± 0.3 4.9 ± 0.4
*Data are presented as mean ± standard error of the mean; †p < 0.05 vs. baseline. BP = blood pressure; BUN = blood urea nitrogen;
Cr = creatinine; GFR = glomerular filtration rate.
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The Figure shows UAI during the 6-month
observation period in the three groups of subjects.
Mean UAI ranged from 213.1 to 328.8 mg/g creatinine
before the administration of drugs. Imidapril was
initially administered to Group 1 subjects, and UAI
gradually decreased during the 6-month observation
period (before: 213.1 ± 46.6; 3 months: 111.6 ± 35.6,
p < 0.001; 6 months: 114.5 ± 35.4 mg/g creatinine,
p < 0.01). In Group 2 subjects who had taken imidapril,
the addition of losartan further decreased UAI from
328.8 ± 87.3 to 185.3 ± 51.4 mg/g creatinine at 3
months (p < 0.05), and to 244.8 ± 88.3 mg/g creatinine
at 6 months. However, the addition of imidapril did
not alter UAI in Group 3 subjects who had taken
losartan.
DISCUSSION
The present study demonstrated the therapeutic efficacy
of the combination of ACEI and ARA to treat
albuminuria in subjects with diabetic nephropathy.
The administration of imidapril alone significantly
reduced UAI, without any change in BUN, serum
creatinine levels and estimated GFR. The drug also
decreased systolic and diastolic blood pressure. Group
1 subjects had fewer diabetic complications than Groups
2 and 3 subjects, and the initial use of ACEI had the
therapeutic efficacy of reducing UAI in Group 1
subjects. Angiotensin II directly constricts efferent
arterioles of glomerulus, and the inhibition of the renin–
angiotensin system could release from intraglomerular
hypertension and glomerular hyperfiltration [21,22].
Direct renoprotective effect as well as decrease in blood
pressure could ameliorate renal impairment in subjects
with diabetic nephropathy.
Subjects in Groups 2 and 3 had already been treated
with either ACEI or ARA, and thus urinary excretion
of albumin might already have been considerably
reduced. It did not seem easy that an additional drug
would produce further reduction in albuminuria. In
Group 2, ARA, added after consecutive therapy with
ACEI, significantly decreased UAI without any
decrease in blood pressure. The magnitude of its
decrement was somewhat equivalent to that in Group 1
subjects, who had initially been treated with ACEI.
In contrast, there was no alteration in albuminuria in
Group 3 subjects, who were given ACEI after treatment
with ARA. The reason for this difference was not
determined, but we may consider several possibilities
regarding the pharmacologic properties of ACEI and
ARA. Chronic administration of ACEI might not totally
block the conversion of angiotensin I to angiotensin II,
and could relatively upregulate the function of
angiotensin AT1 and AT2 receptors. Also, angiotensin
II is partially produced by chymase independently of
angiotensin converting enzyme [20]. Under these
circumstances, the addition of ARA would abolish the
alternative changes and further reduce UAI in Group
2. After the inhibition of AT1 receptor binding by
ARA, the conversion of angiotensin I to angiotensin
II could be augmented. The addition of ACEI
diminished its augmented conversion, but there was
no benefit in reducing albuminuria when adding ACEI
to consecutive ARA therapy in Group 3. Previous
studies have demonstrated the efficacy of combination
therapy in diabetic nephropathy [24,25]. In those
studies, the administration of ACEI and ARA was
started simultaneously, and the effectiveness was
evaluated by comparing with the single use of either
ACEI or ARA. There is only one previous report of
either ACEI or ARA added after initial therapy with
the other agent [23]. The present finding may thus
indicate that ARA has a dominant effect on
diminishing albuminuria in diabetic nephropathy.
Further studies will be necessary to obtain conclusive
evidence of the efficacy of combination therapy with
ACEI and ARA.
In conclusion, we determined whether combination
therapy with ACEI and ARA is a useful tool for reducing
albuminuria in diabetic nephropathy. Initial use of ACEI
profoundly decreased albuminuria. The addition of
ARA to consecutive ACEI therapy further reduced
albuminuria in subjects with advanced renal
impairment, but the addition of ACEI to consecutive
ARA therapy did not. These results indicate that the
addition of ARA to consecutive ACEI therapy augments
a protective effect against the progression of diabetic
nephropathy.
Figure. Urinary albumin index (UAI) during the 6-month
observation period in the three groups of subjects with diabetic
nephropathy. Group 1 subjects were treated with imidapril. Group
2 subjects had losartan added to consecutive therapy with imidapril.
Group 3 subjects had imidapril added to consecutive therapy with
losartan. Values are mean ± standard error of the mean. *p < 0.05
vs. baseline.
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